Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Bidridistrogene xeboparvovec by Sarepta Therapeutics for Limb-Girdle Muscular Dystrophy: Likelihood of Approval
Bidridistrogene xeboparvovec is under clinical development by Sarepta Therapeutics and currently in Phase III for Limb-Girdle Muscular Dystrophy. According to...
Risk adjusted net present value: What is the current valuation of Sarepta Therapeutics's Bidridistrogene xeboparvovec?
Bidridistrogene xeboparvovec is a gene therapy commercialized by Sarepta Therapeutics, with a leading Phase III program in Limb-Girdle Muscular Dystrophy....
Risk adjusted net present value: What is the current valuation of Sarepta Therapeutics's Bidridistrogene xeboparvovec?
Bidridistrogene xeboparvovec is a gene therapy commercialized by Sarepta Therapeutics, with a leading Phase III program in Limb-Girdle Muscular Dystrophy....